JP2022532865A5 - - Google Patents

Info

Publication number
JP2022532865A5
JP2022532865A5 JP2021564704A JP2021564704A JP2022532865A5 JP 2022532865 A5 JP2022532865 A5 JP 2022532865A5 JP 2021564704 A JP2021564704 A JP 2021564704A JP 2021564704 A JP2021564704 A JP 2021564704A JP 2022532865 A5 JP2022532865 A5 JP 2022532865A5
Authority
JP
Japan
Prior art keywords
patient
composition according
grade
administered
neurotoxicity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021564704A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022532865A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/031231 external-priority patent/WO2020227177A1/en
Publication of JP2022532865A publication Critical patent/JP2022532865A/ja
Publication of JP2022532865A5 publication Critical patent/JP2022532865A5/ja
Priority to JP2025013168A priority Critical patent/JP2025069275A/ja
Pending legal-status Critical Current

Links

JP2021564704A 2019-05-03 2020-05-03 キメラ抗原受容体免疫療法の投与方法 Pending JP2022532865A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025013168A JP2025069275A (ja) 2019-05-03 2025-01-29 キメラ抗原受容体免疫療法の投与方法

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201962843190P 2019-05-03 2019-05-03
US62/843,190 2019-05-03
US201962855828P 2019-05-31 2019-05-31
US62/855,828 2019-05-31
US201962868262P 2019-06-28 2019-06-28
US62/868,262 2019-06-28
US201962931669P 2019-11-06 2019-11-06
US62/931,669 2019-11-06
US201962944903P 2019-12-06 2019-12-06
US62/944,903 2019-12-06
PCT/US2020/031231 WO2020227177A1 (en) 2019-05-03 2020-05-03 Methods of administering chimeric antigen receptor immunotherapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025013168A Division JP2025069275A (ja) 2019-05-03 2025-01-29 キメラ抗原受容体免疫療法の投与方法

Publications (2)

Publication Number Publication Date
JP2022532865A JP2022532865A (ja) 2022-07-20
JP2022532865A5 true JP2022532865A5 (cg-RX-API-DMAC7.html) 2023-05-15

Family

ID=73050885

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021564704A Pending JP2022532865A (ja) 2019-05-03 2020-05-03 キメラ抗原受容体免疫療法の投与方法
JP2025013168A Pending JP2025069275A (ja) 2019-05-03 2025-01-29 キメラ抗原受容体免疫療法の投与方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025013168A Pending JP2025069275A (ja) 2019-05-03 2025-01-29 キメラ抗原受容体免疫療法の投与方法

Country Status (13)

Country Link
US (2) US20200384027A1 (cg-RX-API-DMAC7.html)
EP (2) EP4249075A3 (cg-RX-API-DMAC7.html)
JP (2) JP2022532865A (cg-RX-API-DMAC7.html)
KR (2) KR20220005075A (cg-RX-API-DMAC7.html)
CN (3) CN114206346A (cg-RX-API-DMAC7.html)
AU (2) AU2020267378B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021021996A2 (cg-RX-API-DMAC7.html)
CA (1) CA3138707A1 (cg-RX-API-DMAC7.html)
IL (1) IL287533A (cg-RX-API-DMAC7.html)
MX (1) MX2021013394A (cg-RX-API-DMAC7.html)
SG (1) SG11202112123RA (cg-RX-API-DMAC7.html)
TW (1) TW202108150A (cg-RX-API-DMAC7.html)
WO (1) WO2020227177A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114206346A (zh) * 2019-05-03 2022-03-18 凯德药业股份有限公司 施用嵌合抗原受体免疫疗法的方法
AU2021391623A1 (en) * 2020-12-04 2023-06-29 Incyte Corporation Anti-cd19 combination therapy
WO2022137186A1 (en) * 2020-12-23 2022-06-30 Crispr Therapeutics Ag Cancer treatment using cd38 inhibitor and/or lenalidomide and t-cells expressing a chimeric antigen receptor
CA3203531A1 (en) 2020-12-30 2022-07-07 Simon Olivares Recombinant vectors comprising polycistronic expression cassettes and methods of use thereof
CN117295507A (zh) * 2021-05-14 2023-12-26 凯德药业股份有限公司 嵌合抗原受体t细胞疗法
CN113406334A (zh) * 2021-06-02 2021-09-17 浙江省人民医院 一种dlbcl相关的生物标记组合物及其应用、dlbcl预后的效果预测模型
KR20240027077A (ko) * 2021-07-30 2024-02-29 카이트 파마 인코포레이티드 세포 요법-유도 독성의 모니터링 및 관리
CN113786490A (zh) * 2021-09-14 2021-12-14 华中科技大学同济医学院附属协和医院 能调控巨噬细胞表观遗传的制剂用于制备治疗噬血细胞综合征药物的应用
CN117357637A (zh) * 2022-06-30 2024-01-09 上海优卡迪生物医药科技有限公司 一种治疗肿瘤的联合用药物组合物及其用途
WO2026092543A1 (en) * 2024-10-29 2026-05-07 Shenzhen Genocury Biotech Co., Ltd Methods and compositions of prophylactic therapy for preventing crs

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5728388A (en) 1989-10-03 1998-03-17 Terman; David S. Method of cancer treatment
US6319494B1 (en) 1990-12-14 2001-11-20 Cell Genesys, Inc. Chimeric chains for receptor-associated signal transduction pathways
IL104570A0 (en) 1992-03-18 1993-05-13 Yeda Res & Dev Chimeric genes and cells transformed therewith
AU687763B2 (en) 1992-10-20 1998-03-05 Central Laboratory Of The Netherlands Red Cross Blood Transfusion Service Interleukin-6 receptor antagonists
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
US6406699B1 (en) 1999-10-05 2002-06-18 Gary W. Wood Composition and method of cancer antigen immunotherapy
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
HK1052372A1 (zh) 2000-02-24 2003-09-11 Xcyte Therapies, Inc. 细胞的同步刺激和富集
GB0700058D0 (en) 2007-01-03 2007-02-07 Scancell Aps Anti-tumor vaccine based on normal cells
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
EP3018145B1 (en) * 2010-10-27 2018-04-04 Amgen Research (Munich) GmbH Means and methods for treating dlbcl
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
JP2014509841A (ja) 2011-01-18 2014-04-24 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 癌を治療するための組成物および方法
WO2012129514A1 (en) 2011-03-23 2012-09-27 Fred Hutchinson Cancer Research Center Method and compositions for cellular immunotherapy
EP2532740A1 (en) 2011-06-11 2012-12-12 Michael Schmück Antigen-specific CD4+ and CD8+ central-memory T cell preparations for adoptive T cell therapy
KR20140060541A (ko) 2011-09-16 2014-05-20 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 암을 치료하기 위한 rna 조작된 t 세포
US10117896B2 (en) 2012-10-05 2018-11-06 The Trustees Of The University Of Pennsylvania Use of a trans-signaling approach in chimeric antigen receptors
KR20240164967A (ko) 2014-02-04 2024-11-21 카이트 파마 인코포레이티드 B 세포 악성종양 및 다른 암을 치료하는데 유용한 자가 t 세포 및 그의 조성물의 생산 방법
KR102349677B1 (ko) 2015-05-28 2022-01-12 카이트 파마 인코포레이티드 T 세포 요법을 위해 환자를 컨디셔닝하는 방법
IL292504B2 (en) 2015-10-20 2024-01-01 Kite Pharma Inc -methods of preparing t cells for t cell therapy
CN108495651A (zh) 2015-12-17 2018-09-04 诺华股份有限公司 抗pd-1的抗体分子及其用途
EP3484455A2 (en) * 2016-07-15 2019-05-22 Novartis AG Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
BR102018008260A2 (pt) * 2017-04-24 2020-04-28 Kite Pharma, Inc. domínios de ligação ao antígeno humanizado e métodos de uso
IL327498A (en) * 2017-06-02 2026-05-01 Juno Therapeutics Inc Articles of manufacture and methods for treatment using adoptive cell therapy
CN111757744A (zh) * 2017-10-02 2020-10-09 人源股份有限公司 使用gm-csf拮抗剂治疗免疫疗法相关毒性的方法
EP3697500A1 (en) * 2017-10-18 2020-08-26 Kite Pharma, Inc. Methods of administering chimeric antigen receptor immunotherapy
CN114206346A (zh) * 2019-05-03 2022-03-18 凯德药业股份有限公司 施用嵌合抗原受体免疫疗法的方法

Similar Documents

Publication Publication Date Title
JP2024156736A5 (cg-RX-API-DMAC7.html)
Liu et al. PD-1/PD-L1 inhibitors in cervical cancer
Antonia et al. Immuno-oncology combinations: a review of clinical experience and future prospects
Goldstein et al. Drug-associated polymyalgia rheumatica/giant cell arteritis occurring in two patients after treatment with ipilimumab, an antagonist of ctla-4.
Peng et al. Chemotherapy induces programmed cell death-ligand 1 overexpression via the nuclear factor-κB to foster an immunosuppressive tumor microenvironment in ovarian cancer
Li et al. IDO1: an important immunotherapy target in cancer treatment
JP2022078265A5 (cg-RX-API-DMAC7.html)
JP2019516748A5 (cg-RX-API-DMAC7.html)
Behnamfar et al. Levonorgestrel-releasing intrauterine system (Mirena) in compare to medroxyprogesterone acetate as a therapy for endometrial hyperplasia
JP2014533279A5 (cg-RX-API-DMAC7.html)
Xiao et al. Application of PARP inhibitors combined with immune checkpoint inhibitors in ovarian cancer
JP2008515890A5 (cg-RX-API-DMAC7.html)
JP2018522851A5 (cg-RX-API-DMAC7.html)
Lyons et al. Bispecific T-cell engagers in childhood B-acute lymphoblastic leukemia
JP2023521227A5 (cg-RX-API-DMAC7.html)
JP2022527373A5 (cg-RX-API-DMAC7.html)
Duong et al. T cell Immunoglobulin and mucin domain containing protein 3 (TIM-3) inhibitors in oncology clinical trials: a review
JPWO2020250915A5 (cg-RX-API-DMAC7.html)
Maggiore et al. Chemotherapy, targeted therapy and immunotherapy: Which drugs can be safely used in the solid organ transplant recipients?
Spies et al. Prednisone chronotherapy
MX2022001403A (es) Metodos de administracion de anticuerpos anti-siglec-8 y corticosteroides.
Nastoupil et al. CELESTIMO: a phase III trial evaluating the efficacy and safety of mosunetuzumab plus lenalidomide versus rituximab plus lenalidomide in patients with relapsed or refractory follicular lymphoma who have received≥ 1 line of systemic therapy
Zhang et al. Efficacy and safety of CD19-specific CAR-T cell-based therapy in secondary central nervous system lymphoma
Gao et al. Lb0009 allogenic cd19 car nk cell therapy in refractory systemic lupus erythematosus-a case series study
Diéras et al. Phase I combining a P-glycoprotein inhibitor, MS209, in combination with docetaxel in patients with advanced malignancies